Regenxbio Inc (NASDAQ:RGNX) shares, rose in value on Friday, July 11, with the stock price down by -4.19% to the previous day’s close as strong demand from buyers drove the stock to $8.68.
Actively observing the price movement in the last trading, the stock closed the session at $9.06, falling within a range of $8.6134 and $9.1. The value of beta (5-year monthly) was 1.089. Referring to stock’s 52-week performance, its high was $15.36, and the low was $5.03. On the whole, RGNX has fluctuated by -11.52% over the past month.
With the market capitalization of Regenxbio Inc currently standing at about $437.37 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RGNX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of RGNX currently trading nearly -0.38% and -3.17% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.67, while the 7-day volatility ratio is showing 5.30% which for the 30-day chart, stands at 6.96%. Furthermore, Regenxbio Inc (RGNX)’s beta value is 1.10.
A comparison of Regenxbio Inc (RGNX) with its peers suggests the former has fared considerably weaker in the market. RGNX showed an intraday change of -4.19% in last session, and over the past year, it grew by 12.29%%.
Data on historical trading for Regenxbio Inc (NASDAQ:RGNX) indicates that the trading volumes over the past 10 days have averaged 0.66 and over the past 3 months, they’ve averaged 1.09 million. According to company’s latest data on outstanding shares, there are 50.12 million shares outstanding.
Nearly 9.38% of Regenxbio Inc’s shares belong to company insiders and institutional investors own 86.68% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.51 million shares as on 2025-06-13, resulting in a short ratio of 4.42. According to the data, the short interest in Regenxbio Inc (RGNX) stood at 1329.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 6.3 million. The stock has fallen by -18.04% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RGNX stock heading into the next quarter.
